129 results on '"Eugen-Olsen, Jesper"'
Search Results
2. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*
3. Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood
4. Early sepsis recognition: how difficult can this be?
5. Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE)
6. Self-rated health and chronic inflammation are related and independently associated with hospitalization and long-term mortality in the general population
7. Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome
8. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
9. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department
10. qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial
11. Prospective and External Validation of Prognostic Machine Learning Models for Short- and Long-Term Mortality Among Acutely Admitted Patients Based on Blood Tests
12. Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor)
13. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
14. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
15. Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood
16. Capacidad del biomarcador suPAR para estratificar el pronóstico en pacientes atendidos en servicios de urgencias hospitalarios.
17. Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes
18. Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
19. suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury
20. Supplementary Table A2 from Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
21. Supplementary Figure A1 from Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
22. Supplementary Table and Figure Legends from Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
23. Challenges facing the clinical adoption of a new prognostic biomarker: a case study
24. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
25. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
26. Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery
27. Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
28. Clinical, genetic, and experimental increase in soluble urokinase plasminogen activator receptor levels promotes atherosclerosis
29. Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease
30. Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study
31. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
32. IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19
33. Soluble Urokinase Receptor Levels Are Not Affected by the Systemic Inflammatory Response to Anesthesia and Operative Trauma
34. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
35. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
36. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome
37. Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department
38. Circulating suPAR associates with severity and in‐hospital progression of COVID‐19.
39. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department.
40. suPAR inflames kidneys with T cells and aggravates sepsis-induced acute kidney injury.
41. Overall and Interindividual Effect of Four Different Drug Classes on Soluble Urokinase Plasminogen Activator Receptor in Albuminuric Type 1 and Type 2 Diabetes
42. Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19.
43. Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department.
44. OBESITY, INFLAMMATION AND CLINICAL OUTCOMES IN COVID-19: PRE- AND POST-OMICRON.
45. Obesity, Inflammation, and Clinical Outcomes in COVID-19: A Multicenter Prospective Cohort Study.
46. Development and validation of prognostic machine learning models for short- and long-term mortality among acutely admitted patients based on blood tests.
47. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
48. Value of the soluble urokinase-type plasminogen activator receptor as a predictor of prognosis in patients attended in hospital emergency departments.
49. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.
50. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.